Biofidelity & CellCarta Collaborate on Lung Cancer Diagnostics

Biofidelity, a pioneer in genomic solutions, has partnered with CellCarta, a global leader in precision medicine services, to bring Aspyre® Lung, an innovative diagnostic platform, to clinical trials worldwide. This collaboration is set to transform how non-small cell lung cancer (NSCLC) biomarkers are detected, speeding up patient enrollment and advancing research to deliver better outcomes for patients.

Simplifying Lung Cancer Diagnostics

Aspyre Lung streamlines the process of identifying key NSCLC biomarkers by analyzing both DNA and RNA from tissue and blood samples. Its efficient four-step workflow is designed to integrate easily into existing laboratory setups using qPCR platforms, making it accessible for labs worldwide. This aligns perfectly with CellCarta’s mission of advancing clinical trials through cutting-edge genomic services.

The partnership begins with CellCarta validating Aspyre Lung in its European laboratories, with plans to expand to the United States. By enabling the use of both liquid and tissue biopsy samples, this collaboration ensures a smoother, faster process for patient recruitment, helping clinical trials progress more efficiently and effectively.

Leaders Share Their Vision

“We’re delighted to team up with CellCarta to bring the benefits of Aspyre Lung to global clinical trials,” said Barnaby Balmforth, PhD, CEO and Co-Founder of Biofidelity. “At Biofidelity, we’re driven by a vision of making genomic testing more accessible. This partnership brings us closer to that goal by simplifying genomic profiling for NSCLC and making clinical trial enrollment faster and more efficient.”

CellCarta CEO Dusty Tenney shared similar enthusiasm: “This collaboration with Biofidelity adds an exciting dimension to our biomarker testing capabilities. Aspyre Lung strengthens our portfolio of precision medicine services, helping us offer tailored solutions that drive advancements in healthcare and accelerate progress in lung cancer treatment.”

A Partnership for Progress in Precision Medicine

This collaboration highlights a shared commitment to improving the future of lung cancer research and treatment. By combining Biofidelity’s innovative diagnostic technology with CellCarta’s expertise in clinical trials, the partnership ensures a smoother pathway from discovery to patient care. Together, they aim to make a lasting difference in the fight against lung cancer.